4971 results for "Psychedelics"
Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – June 01, 2025
Summary
No Summary
Abstract
3-Methylmethcathinone (3-MMC) is a designer drug that belongs to the group of synthetic cathinones. The compound has been scheduled in many jurisdi...
Advances in brain and religion studies: a review and synthesis of recent representative studies.
Frontiers in human neuroscience – January 01, 2024
Summary
No Summary
Abstract
We review and synthesize recent religion and brain studies and find that at a broad network neuroscience level, religious/spiritual experiences (RS...
Psychotomimetic compensation versus sensitization.
Pharmacology research & perspectives – August 01, 2024
Summary
No Summary
Abstract
It is a paradox that psychotomimetic drugs can relieve symptoms that increase risk of and cooccur with psychosis, such as attention and motivationa...
Exploring the transformative potential of out-of-body experiences: A pathway to enhanced empathy.
Neuroscience and biobehavioral reviews – August 01, 2024
Summary
No Summary
Abstract
Out-of-body experiences (OBEs) are subjective phenomena during which individuals feel disembodied or perceive themselves as outside of their physic...
Feasibility and effectiveness study of applying a hallucinogen harm reduction and integration model to a mindfulness thinking intervention using virtual reality: A randomized controlled trial.
Digital health – January 01, 2024
Summary
No Summary
Abstract
The purpose of this study was to investigate whether a virtual reality (VR) program designed and developed based on the hallucinogenic harm reducti...
Awake or Sleeping? Maybe Both… A Review of Sleep-Related Dissociative States.
Journal of clinical medicine – June 06, 2023
Summary
No Summary
Abstract
Recent studies have begun to understand sleep not only as a whole-brain process but also as a complex local phenomenon controlled by specific neuro...
First few seconds for flow: A comprehensive proposal of the neurobiology and neurodynamics of state onset.
Neuroscience and biobehavioral reviews – December 01, 2022
Summary
No Summary
Abstract
Flow is a cognitive state that manifests when there is complete attentional absorption while performing a task. Flow occurs when certain internal a...
Ketamine and sleep modulate neural complexity dynamics in cats.
The European journal of neuroscience – March 01, 2022
Summary
No Summary
Abstract
There is increasing evidence that the level of consciousness can be captured by neural informational complexity: for instance, complexity, as measu...
EEG Signal Diversity Varies With Sleep Stage and Aspects of Dream Experience
Frontiers in Psychology – April 23, 2021
Summary
The vividness of our inner **Dream** worlds during **Sleep** correlates with brain activity. New **Neuroscience** insights from **Sleep and Wakefulness Research** using **Electroencephalography** on healthy volunteers reveal that while brain signal diversity decreases with deeper **Slow-wave sleep**, the **Neural dynamics and brain function** of the posterior cortex positively correlate with the thought-perceptual nature of dream content. This **Cognitive psychology** finding, impacting our understanding of **Consciousness** and **Perception**, suggests the richness of dreams, much like **Mind-wandering** in **Wakefulness**, is reflected in measurable brain complexity.
Abstract
Several theories link consciousness to complex cortical dynamics, as suggested by comparison of brain signal diversity between conscious states and...
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.
Journal of psychopharmacology (Oxford, England) – March 01, 2022
Summary
No Summary
Abstract
Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin Am...
Absorption and spiritual experience: A review of evidence and potential mechanisms.
Consciousness and cognition – August 01, 2019
Summary
No Summary
Abstract
Some people seem to have a 'talent' for spiritual experience: they readily sense the presence of supernatural beings, receive special messages from...
[Anorexia, bulimia, and binge eating disorder : current situation and future prospects].
Revue medicale suisse – February 12, 2025
Summary
No Summary
Abstract
Eating is essential to the survival of any living organism. However, beyond simple nutrition, eating is a source of pleasure that awakens a host of...
Emerging medications and pharmacological treatment approaches for substance use disorders.
Pharmacology, biochemistry, and behavior – March 01, 2025
Summary
No Summary
Abstract
Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have c...
Placebo Effects: Neurological Mechanisms Inducing Physiological, Organic, and Belief Responses-A Prospective Analysis.
Healthcare (Basel, Switzerland) – November 20, 2024
Summary
No Summary
Abstract
The placebo effect can induce physiological or clinical neurological and organic responses despite the recipient receiving no active ingredients; t...
[Epigenetic changes in alcohol addiction and therapeutic perspectives].
Annales pharmaceutiques francaises – January 01, 2025
Summary
No Summary
Abstract
Alcohol consumption is a major public health issue. Patients with Alcohol Use Disorder (AUD) can benefit from five treatments that preferentially t...
Tags
Initiation and/or re-initiation of drug use among people who use drugs in Vancouver, Canada from 2021 to 2022: a prospective cohort study.
Substance abuse treatment, prevention, and policy – September 10, 2024
Summary
No Summary
Abstract
Widespread health service disruptions resulting from the COVID-19 pandemic coincided with a dramatic increase in overdose deaths among people who u...
Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness.
Communications biology – September 19, 2024
Summary
No Summary
Abstract
Disorders of consciousness (DoC) represent a challenging and complex group of neurological conditions characterised by profound disturbances in con...
Novel rapid treatment options for adolescent depression.
Pharmacological research – March 01, 2024
Summary
No Summary
Abstract
There is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selecti...
Targeting metaplasticity mechanisms to promote sustained antidepressant actions.
Molecular psychiatry – April 01, 2024
Summary
No Summary
Abstract
The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine (esketamine) rapidly induce antidepressant effects and promot...
Polydrug Use Typologies of Regular Ecstasy Users Visiting Electronic Dance Music Events: A Latent Class Analysis.
European addiction research – January 01, 2024
Summary
No Summary
Abstract
Polydrug use patterns among young adults using ecstasy vary, as well as their willingness to change them. Polydrug use patterns are likely associat...
Mechanisms of SSRI Therapy and Discontinuation.
Current topics in behavioral neurosciences – January 01, 2024
Summary
No Summary
Abstract
SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health...
Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis.
Current neuropharmacology – January 01, 2024
Summary
No Summary
Abstract
We conducted a scientometric analysis to outline clinical research on posttraumatic stress disorder (PTSD). Our primary objective was to perform a ...
The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement.
Drug and alcohol dependence – December 01, 2023
Summary
No Summary
Abstract
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (...
Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects.
Ibrain – January 01, 2023
Summary
No Summary
Abstract
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are the most common causes of emotional distress that impair an individual...
The role of neurotrophic factors in novel, rapid psychiatric treatments.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2024
Summary
No Summary
Abstract
Neurotrophic factors are a family of growth factors that modulate cellular growth, survival, and differentiation. For many decades, it has been gen...
Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Missouri medicine – January 01, 2023
Summary
No Summary
Abstract
The 21st century has brought novel therapies and new therapeutic targets for major depressive disorder (MDD). Until recently all antidepressant med...
Perioperative Considerations for Patients Exposed to Psychostimulants.
Anesthesia and analgesia – September 01, 2023
Summary
No Summary
Abstract
Concerns regarding the perioperative management of acute psychostimulant intoxication have been recognized for decades, but novel and diverse subst...
Overview of Alcohol Use Disorder.
The American journal of psychiatry – August 01, 2023
Summary
No Summary
Abstract
Alcohol is regularly consumed throughout most of the world, including by nearly half the U.S. population age 12 or older. Heavy drinking, which is ...
Age, Dose, and Locomotion: Decoding Vulnerability to Ketamine in C57BL/6J and BALB/c Mice.
Biomedicines – June 25, 2023
Summary
No Summary
Abstract
Ketamine has been abused as a psychedelic agent and causes diverse neurobehavioral changes. Adolescence is a critical developmental stage but vulne...
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.
Focus (American Psychiatric Publishing) – July 01, 2023
Summary
No Summary
Abstract
Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride a...
Retigabine promotes ketamine's antidepressant effect in the forced swim test in male and female C57BL/6J mice.
Pharmacology, biochemistry, and behavior – September 01, 2023
Summary
No Summary
Abstract
Ketamine has been increasingly used as a rapid-onset antidepressant in specific clinical settings. However, as a psychedelic reagent, the potential...
Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants.
Frontiers in psychiatry – January 01, 2023
Summary
No Summary
Abstract
The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting anti...
How should we design future mechanistic and/or efficacy clinical trials?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2024
Summary
No Summary
Abstract
The emergence of new molecular targets, together with the development of new approaches to neuropsychiatric diseases, involving psychedelics as wel...
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.
Expert review of neurotherapeutics – June 01, 2023
Summary
No Summary
Abstract
Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry...
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review.
Current neuropharmacology – January 01, 2024
Summary
No Summary
Abstract
This narrative state-of-the-art review paper describes the progress in the understanding and treatment of Posttraumatic Stress Disorder (PTSD). Ove...
From recent advances in underlying neurocircuitry of fear and anxiety to promising pharmacotherapies for PTSD: The saga of heart, sex and the developing brain.
Neuropharmacology – July 01, 2023
Summary
No Summary
Abstract
Available pharmacotherapies for anxiety disorders and post-traumatic stress-disorder (PTSD) have limited efficacy, but no new anxiolytic drug has b...
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.
JAMA psychiatry – January 01, 2023
Summary
No Summary
Abstract
Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD tr...
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy.
Human psychopharmacology – May 01, 2020
Summary
No Summary
Abstract
Ayahuasca is a hallucinogenic plant preparation, traditionally consumed in sacred ceremonies by indigenous North-Westerner Amazonian countries like...
Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?
Medical Sciences – November 20, 2025
Summary
Chronic pain affects nearly one in five adults globally, demanding new solutions beyond opioids. Psilocybin emerges as a promising therapy, addressing both physical and emotional aspects. Preclinical investigations show it encourages brain cell growth and reduces inflammation, leading to lasting pain relief in animal models of nerve and inflammatory pain. Early human trials, though limited, indicate improved mood, reduced anxiety, and better quality of life for patients with chronic conditions, alongside preliminary pain relief. This multidimensional approach offers hope for a major healthcare burden.
Abstract
Background: Chronic pain affects nearly one in five adults worldwide and remains a major healthcare burden due to its persistence, multidimensional...
Novel approaches for drug development against chronic primary pain: A systematic review.
British journal of pharmacology – November 14, 2025
Summary
Millions suffer from chronic primary pain, yet traditional treatments often fall short. A comprehensive review of clinical trials aimed to identify novel and repurposed drug approaches for conditions like fibromyalgia, complex regional pain syndrome, and chronic low back pain. While a definitive breakthrough is still sought, promising candidates targeting cannabinoid, glutamate, GABAergic, neuroinflammatory, and immune mechanisms are emerging, demonstrating efficacy and safety. Notably, cannabidiol and ketamine show broad potential, having been tested for all three pain types. Focused drug development in these specific areas offers significant hope for improved pain management.
Abstract
Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is...
Biosynthesis, total synthesis, and biological profiles of Ergot alkaloids.
The Alkaloids. Chemistry and biology – January 01, 2021
Summary
LSD's discovery sparked intense interest in ergot alkaloids. Research explores their biosynthesis and total synthesis, revealing how natural products like Chanoclavine and Clavicipitic acid form the ergoline scaffold. New chemical methodologies enable efficient production of these indole-based compounds, including Lysergic acid, Lysergol, and Isolysergol. Understanding the structure-activity relationship of alkaloids like Aurantioclavine, Cycloclavine, and Rugulovasine advances pharmaceutical chemistry, offering new avenues for treating neurological disorders.
Abstract
While the use of ergot alkaloids in folk medicine has been practiced for millennia, systematic investigations on their therapeutic potential began ...
Near-death experience as mystical experience.
Journal of religion and health – March 01, 1986
Summary
Many people report profound self-transformation after near-death experiences, a phenomenon often associated with mystical awareness. A detailed nine-category typology of mystical experience was applied to these accounts, revealing strong parallels. This framework successfully characterizes near-death experiences, positively defining them as a distinct mystical state.
Abstract
Near-death experience exhibits many attributes of mystical awareness. Assessing the mystical quality of psychedelic experience, Walter Pahnke ident...
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
Drug and alcohol dependence – June 01, 2012
Summary
Surprisingly, despite its structural links to migraine medications, psilocybin frequently causes headaches. A controlled investigation with healthy volunteers explored various doses, revealing headaches were a common, dose-dependent effect. These headaches had a delayed onset, were transient, and typically resolved within a day. Importantly, they were neither severe nor disabling, suggesting this temporary side effect should not hinder promising future research.
Abstract
Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical u...
Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment
OpenAlex – January 02, 2025
Summary
Psilocybin notably increases the brain's susceptibility to change, while escitalopram reduces it, yet both successfully promote healthier brain states for individuals experiencing depression. Through advanced Computer science modeling of Functional Brain Connectivity Studies, Neuroscience is revealing how the brain's Hierarchy of information processing reconfigures. These insights, vital for Psychology and Medicine, demonstrate psilocybin's ability to open a "window of plasticity," enabling optimal transitions towards improved mental well-being. This innovative approach promises to refine antidepressant therapies, potentially impacting the economics of mental health treatment.
Abstract
Abstract Neural representation can extend beyond localised activity to encompass global patterns, where information is distributed across brain net...
Making a medicine out of MDMA.
The British journal of psychiatry : the journal of mental science – January 01, 2015
Summary
MDMA, once sidelined, is now recognized for its significant therapeutic potential. Evidence suggests it should be reclassified from a drug with no medical use to one with accepted utility. This shift would liberate its use for patients with severe mental illnesses like treatment-resistant PTSD, offering a new avenue for healing.
Abstract
From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical uti...
Is LSD toxic?
Forensic science international – March 01, 2018
Summary
Many believe LSD can be deadly, but evidence shows it's physiologically non-toxic at standard doses. A closer look at deaths attributed to its toxicity reveals other factors. Some fatalities stemmed from massive overdoses. In other cases, agitated individuals under the influence of LSD died following maximal restraint, including hog-tying by police, leading to cardiovascular collapse, likely due to positional asphyxiation. One death was from a different drug entirely. This clarifies that LSD itself is medically safe, challenging the notion of its inherent toxicity.
Abstract
LSD (lysergic acid diethylamide) was discovered almost 75 years ago, and has been the object of episodic controversy since then. While initially ex...
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.
Journal of psychiatric research – May 01, 2022
Summary
Many individuals with severe PTSD also struggle with significant eating disorder symptoms, even without a formal diagnosis. Given the lack of integrated treatment, a trial explored if MDMA-Assisted therapy could effectively reduce these co-occurring issues. Adults with severe PTSD were randomized to receive either MDMA-Assisted therapy or placebo. Their eating disorder symptoms were tracked using the EAT-26 questionnaire. Remarkably, those receiving MDMA-Assisted therapy showed a significant reduction in EAT-26 scores, indicating substantial improvement in eating disorder symptoms compared to the placebo group. This positive treatment effect was particularly strong for women with higher baseline scores. The findings highlight MDMA-Assisted therapy as a highly promising treatment for individuals experiencing both PTSD and eating disorders.
Abstract
Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for E...
Couple Therapy With MDMA-Proposed Pathways of Action.
Front Psychol – November 11, 2021
Summary
Exploring how MDMA could enhance couple therapy reveals promising pathways for relationship healing. This theoretical framework proposes that MDMA, when integrated with therapy, can significantly deepen emotional connection and communication. It suggests mechanisms like reduced fear and heightened empathy, fostering stronger bonding and leading to more positive therapeutic outcomes for couples seeking profound connection.
Abstract
Couple Therapy With MDMA-Proposed Pathways of Action.
Have Norwegians tried psilocybin, and do they accept it as a medicine?
Journal of Psychedelic Studies – April 16, 2021
Summary
Remarkably, 51% of Norwegians are open to psilocybin as medicine, a promising development for upcoming clinical trials in psychiatry and psychology. This hallucinogen, known from ancient archaeological contexts and refined through chemical synthesis, is increasingly vital in drug studies. A survey of 1,078 Norwegian adults revealed 8% had previously used psilocybin. This public openness suggests a favorable environment for clinical psychology and medicine to explore psilocybin's therapeutic potential, facilitating rigorous clinical trials.
Abstract
Abstract Background Psilocybin is emerging as a promising therapeutic agent for a wide range of psychiatric conditions, and clinical trials on psil...
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
OpenAlex – June 07, 2024
Summary
Psilocin, psilocybin's active form, dramatically enhances neuroplasticity in human cortical neurons derived from stem cells. Neuroscience reveals it reshapes neural dynamics and brain function, potentially explaining its psychological benefits. Psilocin decreased surface 5-HT2A receptors, boosted BDNF, and altered gene expression, priming neurons for change. Morphologically, these cortical neurons became more complex with increased synaptic proteins, showing heightened excitability and network activity. This suggests psilocin induces a state of enhanced brain adaptability, crucial for treating conditions linked to synaptic dysfunction.
Abstract
Abstract Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that ps...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study
Psychedelic Medicine – December 23, 2025
Summary
A pioneering group psychotherapy intervention, integrating Psilocybin, offers a new approach for mental health. An FDA-approved Phase 1 to 2 clinical trial developed a unique group facilitation model for individuals with metastatic cancer experiencing anxiety and existential distress. This intervention, a 3-day retreat, employs a secular ritual based on anthropological rites of passage. Psychotherapists guide participants through preparation, psilocybin dosing, and integration. This clinical psychology model provides communal support, making it a promising step in medicine and psychiatry for cancer patients, showing empirically demonstrated safety and efficacy outcomes.
Abstract
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to d...
‘Magic mushroom’ enzyme mystery solved
C&EN Global Enterprise – August 21, 2017
Summary
For nearly 60 years, scientists have sought to unravel the magic behind Psilocybe "magic mushrooms." Now, the complete enzymatic pathway for psilocybin production is finally revealed. Scientists identified four key enzymes, mastering the art of synthesis to create the compound for the first time. This breakthrough in Fungal Biology and Applications promises to unlock psilocybin's therapeutic potential for anxiety and depression, moving beyond the fungi themselves to large-scale medical production.
Abstract
The euphoria and hallucinations induced from eating Psilocybe "magic mushrooms" have earned the fungi a cult following. Albert Hofmann, a chemist a...
Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence
Psychedelics. – October 28, 2025
Summary
Psilocybin shows striking promise for obsessive-compulsive behaviors, according to a systematic review of 13 investigations. Clinically, single doses rapidly reduced symptoms in patients with OCD and body dysmorphic disorder. Crucially, in a genetic mouse model of compulsive behavior, a single psilocybin administration led to robust, enduring reductions in excessive grooming, effects replicated across independent laboratories. While some animal responses were transient, these lasting anti-compulsive effects in validated models highlight significant therapeutic potential.
Abstract
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsiv...
Overview Of Review (OoR) on PSILOCYBIN in Psychiatric Disorders
OpenAlex – August 04, 2024
Summary
Psilocybin, a potent Hallucinogen, holds significant promise for mental health. A new protocol outlines a comprehensive "Overview of Review" to rigorously assess its therapeutic effects, safety, and adverse reactions across numerous psychiatric disorders. This crucial Psychiatry and Psychology initiative will synthesize extensive findings from existing systematic reviews and meta-analyses of randomized clinical trials. The goal is to consolidate scattered evidence, providing a robust foundation for future Health and Well-being Studies and clinical applications, including potential relevance for Autism Spectrum Disorder research.
Abstract
eview question / Objective This protocol outlines the methodology for an "Overview of Review" (OoR) study which aims to conduct a comprehensive ana...
2018/7/6/curcumin-breast-cancer-therapeutic-agent-to-replace-allopathic-treatments-with-extensive-side-effects
OpenAlex – July 09, 2018
Summary
A remarkable 70% of cancer patients experienced substantial, lasting reductions in depression and anxiety symptoms after psilocybin medicine. Recent trials, including one with 50 advanced breast cancer patients, demonstrated this profound effect. Another study of 30 cancer patients reported similar benefits, with minimal side effect concerns. This novel approach offers a promising direction for cancer treatment, moving beyond traditional pharmacological strategies to improve patient well-being, even for those in intensive care.
Abstract
Cancer patients experience a higher rate of depression and anxiety which can result in negative healthcare outcomes. With the limited treatment opt...
Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change?
Military Medicine – April 21, 2022
Summary
Poor PTSD treatment outcomes may stem from the immune system. A 6-year medical literature review suggests unrestrained cytokine signaling induces epigenetic changes, hardwiring a persistent defensive state. This neuroinflammation, involving cholinergic system withdrawal, promotes chronic stress responses, impacting cortisol. Neuroscience and immunology, potentially via bioinformatics, explain how cytokines alter brain function, affecting tryptophan metabolism in brain disorders. Medicine suggests PTSD might be an evolutionary adaptation, with drugs showing benefit via anti-inflammatory effects impacting neurodegeneration mechanisms.
Abstract
ABSTRACT Introduction Treatment outcomes for PTSD with current psychological therapies are poor, with very few patients achieving sustained symptom...
Psilocybin and Psilocin
OpenAlex – March 09, 2000
Summary
Psilocybin mushrooms are notably more popular than LSD among college students, with 15% reporting use compared to just 5% for LSD. These "mind-revealing" mushrooms, containing psilocybin and psilocin, have a long history, used ritualistically by Mexican Native Americans for thousands of years. Modern recreational appeal extends to younger demographics; a California survey found 3.4% of seventh graders and 8.8% of eleventh graders had used them, often cultivated at home from readily available spores.
Abstract
Abstract Psilocybin and psilocin are indolealkylamines present in Central American Psilocybe species of mushrooms and in Panaeolus mushroom species...
Psilocybin Outside the Clinic
JAMA Psychiatry – November 05, 2025
Summary
Over 7 million Americans reported psilocybin mushroom use last year, coinciding with a sharp rise in poison control calls. Unregulated products show over 20-fold variability in potency, and co-use with cannabis is common, potentially increasing adverse event risks. Clinical trial data, based on controlled environments, do not reflect real-world public use. These trends, particularly among adults aged 19 to 50, raise urgent public health concerns regarding product consistency and harm reduction strategies.
Abstract
Importance Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis l...
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder
Annals of Medicine and Surgery – November 24, 2025
Summary
Psilocybin delivers rapid, sustained relief for major depressive disorder, even when traditional treatments fail. Analysis of clinical studies from 2014 to 2024 reveals it acts on serotonin 5-HT2A receptors, boosting neuroplasticity and brain connectivity to alleviate symptoms. Despite this promising mechanism, its Schedule I classification and societal stigma severely restrict therapeutic application and further investigation. Overcoming these regulatory barriers is vital to integrate psilocybin into mainstream mental health care, unlocking its potential to transform depression treatment.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
Nature and chemistry of bioactive components of wild edible mushrooms
OpenAlex – May 31, 2022
Summary
Mushroom Biology reveals powerful medicinal potential. Lentinan, a polysaccharide from *Lentinula edodes*, is clinically proven for certain cancer types, showcasing the rich biochemistry of Agaricales. Beyond cancer, the chemistry of various fungal species yields potent antimicrobial compounds, like pleuromutilin from *Pleurotus*, combating antibiotic resistance. These natural products from diverse mushrooms offer promising avenues for Herbal Medicine Research Studies and Phytochemistry and Bioactivity Studies, impacting human health through novel therapies and Fungal Biology and Applications.
Abstract
Mushrooms have been used in traditional medicine for centuries, although only relatively recently they have become a subject of intensive studies a...